Lenvatinib capsules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Lenvima
Company
Eisai GmbH (EU authorization holder)
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
EU: Adults with progressive locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine; advanced or unresectable hepatocellular carcinoma without prior systemic therapy; or, with pembrolizumab, advanced or recurrent endometrial cancer after platinum-based treatment when curative surgery or radiation is unsuitable.
Indication source and scope
English EMA EPAR overview and product details accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions